Loading...
Intracerebral hemorrhage accounts for about 15% of strokes. No effective treatment is available for these events (unlike for thrombotic strokes), but use of recombinant activated factor VII (rFVIIa) has shown promise in early trials. To further assess this agent, researchers conducted the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, a randomized, double-blind, placebo-controlled trial involving 122 institutions in 22 countries. Patients received either placebo or rFVIIa (20 μg/kg or 80 μg/kg) within 1 hour after the baseline computed tomography scan and within 4 hours after the onset of symptoms. The primary outcome was the modified Rankin scale score (the same scale used in trials evaluating thrombolytic therapy for stroke) at 9…